APG Asset Management US Inc. Sells 13,086 Shares of DexCom, Inc. (NASDAQ:DXCM)

APG Asset Management US Inc. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 61.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,281 shares of the medical device company's stock after selling 13,086 shares during the period. APG Asset Management US Inc.'s holdings in DexCom were worth $644,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of DXCM. Brophy Wealth Management LLC bought a new stake in DexCom during the 3rd quarter worth about $337,000. Geode Capital Management LLC lifted its position in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock valued at $664,056,000 after purchasing an additional 214,136 shares during the period. Coldstream Capital Management Inc. lifted its holdings in DexCom by 45.3% in the third quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company's stock valued at $781,000 after buying an additional 3,508 shares during the period. Toronto Dominion Bank grew its holdings in DexCom by 3.1% during the 3rd quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company's stock worth $13,711,000 after acquiring an additional 6,227 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of DexCom during the 3rd quarter valued at $1,020,000. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

DexCom Stock Performance

DXCM stock traded up $0.78 during trading hours on Tuesday, reaching $68.17. The stock had a trading volume of 1,487,516 shares, compared to its average volume of 4,182,825. The stock has a market capitalization of $26.73 billion, a PE ratio of 47.67, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The stock has a 50-day simple moving average of $76.49 and a 200 day simple moving average of $76.68. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.